An observational study in Hemodynamic Instability, sponsored by Gorm Greisen. Completed at 2 sites in 2 countries. Open to participants aged Up to 4 Weeks. Per ClinicalTrials.gov, last updated 2023-03-28.
Sponsored by Gorm Greisen · Observational
Feasibility trial on the use of a hybrid optical device integrating time-resolved near-infrared spectroscopy (TRS) and diffuse correlation spectroscopy (DCS) for measurement of cerebral oxygen metabolism and blood flow in neonates.
The device wil be tested in four settings measuring:
The BabyLux project aims to provide a precise, accurate, and robust device to continuously monitor cerebral oxygen metabolism and blood flow in critically ill newborn infants. This will be achieved by combining time resolved near-infrared spectroscopy (TRS) with newly developed diffuse correlation spectroscopy (DCS) in a single device. The innovative aspects of the project are related to the use of advanced solutions, based on state-of-the-art photonic components, which have already been tested in laboratory and clinical tests on adults.
Time Resolved Near-infrared spectroscopy and Diffuse Correlation Spectroscopy
The proposed solution will integrate two advanced photonic techniques, TRS and DCS. Both techniques rely on the use of an optical fibre probe (sensor) to illuminate with very low power near-infrared light the scalp and to collect the diffusively reflected optical signal that has propagated through the scalp and skull, and therefore carries information on the deeper cortical region. The different absorption spectra of oxygenated and deoxygenated haemoglobin in the near-infrared range allows for the non-invasive monitoring of the two species in the cortical tissue.
TRS and DCS prototypes are available and have been technically tested in laboratory settings and successfully validated during preclinical trials on adult volunteers and patients.
Measured TRS/DCS parameters
TRS measures the attenuation and the temporal broadening of relatively short light pulses (pulse duration \~100 ps) through a diffusive medium (e.g. a neonate's head). TRS has the ability to resolve path-lengths (or equivalently time-of-flights) of photons that have propagated through the tissues. This enables TRS to separate the absorption and scattering coefficients allowing for absolute measurements, and to utilize time-gating of path-lengths to emphasize signals from deeper tissues. This is particularly important for separating intra- and extra-cerebral signals for brain monitoring.
DCS relies on the fact that temporal correlation of light fields in turbid media also obeys a diffusion equation, albeit a slightly different one than is used for TRS. Thus DCS shares the light penetration advantages of TRS, but, since DCS explicitly measures red blood cell movement, it provides a direct measure of quantities such as cerebral blood flow (CBF).
The specific combination of DCS and TRS allows for the assessment of cerebral oxygen metabolism and CBF in a complete (i.e. CBF and oxygenation are simultaneously and independently provided), accurate (i.e. based on absolute measurements of optical parameters) and robust (i.e. potentially less affected by artefacts related to superficial systemic activity or sensor/head movements) way.
The aim of this study is to perform clinical measurements using the BabyLux instrument in different clinical real-life settings to validate this new technology in terms of feasibility, repeatability of measurements, and user friendliness in neonatal medicine.
The BabyLux system is tested in four different real-life settings to measure:
Gorm Greisen is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Setting 1 and 2:
Newborn infants immediately after delivery by elective caesarean and on their second day of life.
Setting 3:
Premature infants on mechanical ventilation.
Setting 4:
Neonate infants on ventilatory support
Setting 1 and 2:
Inclusion Criteria:
Exclusion Criteria:
Setting 3:
Inclusion Criteria:
Exclusion Criteria:
Setting 4:
Inclusion Criteria:
Exclusion Criteria:
Infants to be measured immediately after birth and on their second day of life.
Device: BabyLux Neuro-monitor
Infants to be measured while changing ventilator settings to normalize arterial pCO2.
Device: BabyLux Neuro-monitor
Infants to be measured for 24 hours continuously to assess user-friendliness and loss of signal.
Device: BabyLux Neuro-monitor
Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
Cerebral tissue oxygen saturation (StO2) after birth.
Measurement of cerebral haemodynamics immediately after birth.
Time frame: 10 min immediately after umbilical cord clamping.
Precision and repeatability
Test-retest variability estimated by within-subject standard deviation in one-way ANOVA with subject as factor.
Time frame: During second day of life.
Cerebral vaso-reactivity to arterial carbon dioxide
Mean CBFi and tcpCO2 one minute before the change and 15 min after will be used to analyse CBFi-tcpCO2 reactivity.
Time frame: 1 hour after change in ventilator settings.
Assessment of user-friendliness and loss of signal in routine care
Assessed by Likert-scale questionnaire completed by clinical staff.
Time frame: 24 hours of contineous measurements.
Plan to share: Undecided
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gorm Greisen